Moxifloxacine Viatris (Moxifloxacin)

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract and skin.

• Community‑acquired pneumonia: effective treatment to eradicate the causative bacteria and improve clinical outcomes.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms.
• Acute bacterial exacerbation of chronic bronchitis: helps resolve bacterial flare‑ups and restore airway function.
• Skin and skin‑structure infections: combats susceptible Gram‑positive and Gram‑negative pathogens in cutaneous lesions.

• Moxifloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and relaxation of DNA that are essential for replication and transcription, leading to bacterial cell death. The dual targeting of both enzymes enhances potency against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertigo or light‑headedness.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm.
• Clostridioides difficile colitis: severe diarrhea with abdominal pain.
• Hepatotoxicity: elevated liver enzymes or jaundice.

When prescribing moxifloxacin, clinicians should consider several safety precautions to minimize risk.

• Assess patient history: evaluate prior fluoroquinolone exposure and tendon disorders.
• Monitor cardiac status: avoid use in patients with known QT prolongation or arrhythmias.
• Renal and hepatic function: adjust therapy in severe impairment.
• Concomitant medications: review for drugs that may prolong QT or interact significantly.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Moxifloxacin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin.
• NSAIDs (e.g., ibuprofen, diclofenac): increase risk of central nervous system stimulation and seizures.
• Drugs that prolong QT interval (e.g., quinidine, sotalol): may cause serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Corticosteroids: potential increased risk of tendon rupture.
• Theophylline: may raise plasma levels, necessitating dose adjustment.